1. Introduction {#sec1-marinedrugs-17-00534}
===============

Gorgonian corals belonging to the genus *Junceella* (family Ellisellidae) \[[@B1-marinedrugs-17-00534],[@B2-marinedrugs-17-00534],[@B3-marinedrugs-17-00534]\] have been found to produce marine origin briarane-type diterpenoids in abundance \[[@B4-marinedrugs-17-00534]\]. Our recent research into the chemical constituents and properties of a gorgonian coral, *Junceella fragilis* (Ridley 1884) ([Figure 1](#marinedrugs-17-00534-f001){ref-type="fig"}), which was distributed extensively in the waters of Orchid Island (= Lanyu Island), intersection of Kuroshio current and South China Sea surface current, has resulted in the isolation of three new 8- hydroxybriaranes--fragilides R--T (**1**--**3**) ([Figure 1](#marinedrugs-17-00534-f001){ref-type="fig"}). A pro-inflammatory suppression assay was employed to assess the activity of these isolates against the release of inducible nitric oxide synthase (iNOS) from macrophage cells.

2. Results and Discussion {#sec2-marinedrugs-17-00534}
=========================

Fragilide R (**1**) was isolated as an amorphous powder and displayed a pseudomolecular ion at *m/z* 489.20971 in the (+)-HRESIMS, which indicated its molecular formula was C~24~H~34~O~9~ (calcd. for C~24~H~34~O~9~ + Na, 489.20950) (Ω = 8). Both the ^1^H and ^13^C NMR data ([Table 1](#marinedrugs-17-00534-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00534-t002){ref-type="table"}) indicated two acetates (δ~H~ 1.99, 1.94, each 3H × s; δ~C~ 21.3, 21.0, 2 × CH~3~; δ~C~ 170.8, 170.8, 2 × C). Besides the above ester carbonyls, the carbon signal at δ~C~ 176.7 (C) was assigned to a γ-lactone ring along with an oxymethine (δ~H~ 5.97, 1H, d, *J* = 10.2 Hz; δ~C~ 76.4, CH-7). The spectroscopic data, including 1D and 2D NMR experiments ([Figure 2](#marinedrugs-17-00534-f002){ref-type="fig"}), were similar to those of a known metabolite, 9-*O*-deacetyl- umbraculolide A (**4**) \[[@B5-marinedrugs-17-00534]\] ([Figure 1](#marinedrugs-17-00534-f001){ref-type="fig"}), except that the hydroxy group at C-4 in **1** was replaced by a proton in **4**. It is interesting to note that an allylic coupling was observed between H-6 and H~3~-16 (*J* = 1.2 Hz) in the COSY spectrum ([Figure 2](#marinedrugs-17-00534-f002){ref-type="fig"}). In the NOESY spectrum ([Figure 2](#marinedrugs-17-00534-f002){ref-type="fig"}), one of the C-3 methylene protons (δ~H~ 2.96) exhibited a correlation to H-7 and not with H-2, suggesting the β- orientation of this proton. A correlation from H-4 to H-3α (δ~H~ 1.91) as well as the coupling constants between H-4 and H-3α/β (*J* = 5.4, 12.6 Hz), suggested that H-4 was α-oriented according to modeling study. Based on the above findings, the structure, including the relative configuration of stereogenic centers of **1** were assigned as 1*R*\*,2*S*\*,4*R*\*,7*S*\*,8*R*\*,9*S*\*,10*S*\*,14*S*\*, and 17*R*\*, as those of **4** by correlations observed in a NOESY experiment.

One of the C-20 methylene protons (δ~H~ 4.88) showed an NOE correlation to H-9, demonstrating that this olefin proton was H-20b, and the other was assigned as H-20a (δ~H~ 4.97). The proton chemical shifts of the briarane derivatives containing an 11-methylidene group were summarized, and the difference between these two olefin protons (H-20a/b) was smaller than 0.2 ppm, whereas the methylidene-containing six-membered rings exhibited a twisted boat conformation \[[@B6-marinedrugs-17-00534]\]. Owing to the chemical shifts of C-20 methylene protons (δ~H~ 4.97 and 4.88), the conformation of six- membered ring in **1** was concluded to be twisted boat. In a previous study, the absolute configuration of a known chlorinated briarane, junceellin, was established by a single-crystal X-ray diffraction analysis \[[@B7-marinedrugs-17-00534]\]. As briaranes **1**--**3** were isolated along with junceellin from the same organism \[[@B7-marinedrugs-17-00534]\], it is reasonable on biogenetic grounds to assume that **1**--**3** have the same absolute configuration as that of junceellin. Therefore, the configuration of the stereogenic centers of **1** were elucidated as 1*R*,2*S*,4*R*,7*S*,8*R*,9*S*,10*S*,14*S,* and 17*R* ([Figure 2](#marinedrugs-17-00534-f002){ref-type="fig"}), and this compound was found to be the 4β-hydroxy derivative of **4** ([Supplementary Materials, Figures S1--S9](#app1-marinedrugs-17-00534){ref-type="app"}).

Fragilide S (**2**) had a molecular formula C~26~H~33~ClO~9~ as deduced by (+)-ESIMS, which showed a pair of peaks at *m/z* 547/549 \[M + Na\]^+^:\[M + 2 + Na\]^+^ (3:1), suggesting a chlorine atom, and further confirmed by (+)-HRESIMS at *m/z* 547.17055 (calcd. for C~26~H~33~^35^ClO~9~ + Na, 547.17053). The IR spectrum indicated the presence of hydroxy (3447 cm^−1^), γ-lactone (1785 cm^−1^), and ester carbonyl (1733 cm^−1^) groups. The ^13^C NMR data ([Table 2](#marinedrugs-17-00534-t002){ref-type="table"}), showed the presence of a disubstituted olefin (δ~C~ 135.4, CH-4; 129.7, CH-3) and two methylidene groups (δ~C~ 142.6, C-5; 118.8, CH~2~-16; 149.3, C-11; 111.4, CH~2~-20). Moreover, four carbonyl resonances at δ~C~ 174.1, 170.4, 170.1, and 169.2 in the ^13^C spectrum confirmed the presence of a γ-lactone and three other ester groups. In the ^1^H NMR spectrum ([Table 1](#marinedrugs-17-00534-t001){ref-type="table"}), three acetate methyls (δ~H~ 2.09, 2.04, 2.01, each 3H × s) were observed. Moreover, a methyl singlet, a methyl doublet, two aliphatic methines, two pair of aliphatic methylenes, four oxymethines, a chlorinated methine, and a hydroxy proton were observed ([Table 1](#marinedrugs-17-00534-t001){ref-type="table"}).

Analyses of 2D NMR data established a tricyclic nucleus. This assignment was evident from the spin systems from H-2 to H-3, H-3 to H-4, H-6 to H-7, H-9 to H-10, H~2~-12 to H~2~-13, H~2~-13 to H-14, and H-17 to H~3~-18 ([Figure 3](#marinedrugs-17-00534-f003){ref-type="fig"}), while the HMBC between protons and quaternary carbons such as H-2, H-9, H-10, H~3~-15/C-1; H-6, H-16a/C-5; H-6, H-9, H-10, H-17, H~3~-18, OH-8/C-8; H-9, H-10, H-20b/C-11; and H-17, H~3~-18/C-19, revealed the carbon skeleton ([Figure 3](#marinedrugs-17-00534-f003){ref-type="fig"}). The methylidene groups at C-5 and C-11 were confirmed by the HMBC between H~2~-16 to C-4 and C-5, H~2~-20 to C-10, C-11, and C-12, respectively. The C-15 methyl group at C-1 was confirmed by the HMBC between H~3~-15 to C-1, C-2, C-10, and C-14. HMBC spectrum also revealed that the carbon signal at δ~C~ 170.4, 170.1, and 169.2 correlated with the signals of the methyl protons at δ~H~ 2.04, 2.01, and 2.09, respectively, and were assigned as the carbon atom of acetate carbonyl groups. The acetates at C-2, C-9, and C-14 were confirmed from the connectivity between H-2 (δ~H~ 5.47), H-9 (δ~H~ 5.53), and H-14 (δ~H~ 4.84) to the carbonyl carbons of the acetate groups at δ~C~ 170.1, 169.2, and 170.4, respectively. The hydroxy group at C-8 was deduced from the HMBC of a hydroxy proton (δ~C~ 3.11) to C-8 and C-9.

In the NOESY spectrum of **2** ([Figure 3](#marinedrugs-17-00534-f003){ref-type="fig"}), one of the C-16 methylene protons (δ~H~ 5.49) showed a correlation to H-4, demonstrating that this olefinic proton was H-16a and the other was assigned as H-16b (δ~H~ 5.32). Moreover, one of the C-20 methylene protons (δ~H~ 4.76) correlated to H-10, indicating that this proton was H-20b and the other was assigned as H-20a. According to a summary for the chemical shifts of 11-methylidene groups, the configuration of six-membered ring was in a twisted boat conformation \[[@B6-marinedrugs-17-00534]\]. The *E*-geometry of C-3/4 double bond was determined by a large proton coupling constant (*J* = 16.0 Hz) between H-3 and H-4. Correlations between H-10 with H-2 and H-9, while no correlation was seen with Me-15, suggested that H-2, H-9, and H-10 were all in α-oriented. Meanwhile, a correlation of Me-15 with H-14 indicated that H-14 was β-oriented. Furthermore, OH-8 showed correlations with H-4 and H-17, indicating that the hydroxy group at C-8 and proton at C-17 were α-oriented. In addition, H-7 exhibited correlations with H-6 and H~3~-18 but not with OH-8, suggesting that H-7 was β-oriented. Based on above findings, the configuration of stereogenic carbons was determined as 1*R*,2*S*,6*S*,7*R*,8*R*,9*S*,10*S*,14*S* and 17*S* (see [Figures S10--S18 in the Supplementary Materials](#app1-marinedrugs-17-00534){ref-type="app"}).

Compound **3** (fragilide T) has a molecular formula C~32~H~43~ClO~11~ according to its (+)-HRESIMS at *m/z* 661.23866 (calcd. for C~32~H~43~^35^ClO~11~ + Na, 661.23861). Both the ^1^H and ^13^C NMR ([Table 1](#marinedrugs-17-00534-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00534-t002){ref-type="table"}) indicated two acetates (δ~H~ 2.16, 2.00, each 3H × s; δ~C~ 21.3, 20.7, 2 × acetate methyls; 169.7, 169.6, 2 × acetate carbonyls), a propionate (δ~H~ 1.08, 3H, t, *J* = 7.2 Hz; 2.26, 2H, m; δ~C~ 8.8, CH~3~; 27.8, CH~2~; 172.0, propionate carbonyl), and an isovalerate (δ~H~ 0.96, 0.98, each 3H, d, *J* = 6.6 Hz; 2.10, 1H, m; 2.15, 2H, m; δ~C~ 22.6, 22.8, 2 × CH~3~; 25.0, CH; 43.5, CH~2~; 172.6, isovalerate carbonyl). Besides the above ester carbonyls, the carbon signal at δ~C~ 173.9 was assigned to a γ-lactone ring along with an oxymethine (δ~H~ 4.88, 1H, d, *J* = 4.2 Hz; δ~C~ 76.9, CH-7). Two pairs of proton signals at δ~H~ 5.66 and 5.48, and 5.33 and 4.72, correlating to the methylidene signals at δ~C~ 116.4 and 115.2 respectively, were ascribed to two methylidene groups. The tertiary methyl singlet at δ~H~ 1.16 (3H, s) was assigned to H~3~-15 while the secondary methyl doublet at δ~H~ 1.22 (3H, d, *J* = 7.2 Hz) was assigned to H~3~-18. In the HMBC spectrum ([Figure 4](#marinedrugs-17-00534-f004){ref-type="fig"}), the propionoxy group at C-2 was confirmed by the connectivity between H-2 (δ~H~ 6.33) with the carbonyl carbon (δ~C~ 172.0) of propionoxy group. The HMBC also revealed that an acetoxy group at C-9 ([Figure 4](#marinedrugs-17-00534-f004){ref-type="fig"}) and the remaining isovaleroxy and acetoxy groups should be positioned at C-12 or C-14, oxygen-bearing methines, by analysis of characteristic NMR signals (δ~H~ 5.37, 1H, dd, *J* = 5.4, 3.0 Hz; δ~C~ 74.3, CH-12; δ~H~ 4.94, 1H, dd, *J* = 4.2, 3.0 Hz; δ~C~ 73.0, CH-14). However, due to no HMBC detected between H-12 and H-14 and ester carbonyl, the positions of the isovalerate and remaining acetoxy group cannot be determined by HMBC.

Based on previous studies, while the difference between the two olefin protons (H-20a/b) was bigger than 0.3 ppm, the six-membered rings showed a chair conformation \[[@B6-marinedrugs-17-00534]\]. Owing to the chemical shifts of the C-20 methylene protons (δ~H~ 5.33 and 4.72 ppm), the configuration of the methylidene-containing six-membered ring was concluded to exist in a chair conformation. In the NOESY experiment ([Figure 4](#marinedrugs-17-00534-f004){ref-type="fig"}), H-10 correlated to H-2, H-9, and OH-8, but not to H~3~-15, indicating that these protons are located on the same face and can be assigned as α-protons, as C-15 methyl group is a β-substituent at C-1. H-14 was found to exhibit a correlation with H~3~-15, showing that this proton is positioned on the equatorial direction and has a β-orientation at C-14. The *cis* geometry of the C-3/4 double bond was indicated by a 12.0 Hz coupling constant between H-3 (δ~H~ 5.78) and H-4 (δ~H~ 5.96). Moreover, a correlation between H-3 and H~3~-15, and there are correlations which were observed among H-4, H-6, and H-7, further supported the *Z*-form of C-3/4 double bond and indicated that H-6 and H-7 were on the β face. A correlation between OH-8 and H-17 showed that Me-18 at C-17 was β-oriented. The C-12 oxymethine proton (δ~H~ 5.37) was found to couple C-13 methylene protons with coupling constants *J* = 5.4, 3.0 Hz, showing that this proton should be positioned on the equatorial direction and has a β-orientation. Fortunately, a correlation between the methyl protons of acetoxy group at C-9 and methyl protons of isovaleroxy group, indicated that the isovaleroxy group should be located at C-12 by modeling analysis. Thus, based on the above findings, the stereogenic centers were assigned as 1*R*,2*S*,6*S*,7*R*,8*R*,9*S*,10*R*,12*R*,14*S,* and 17*S* (see [Figures S19--S27 in the Supplementary Materials](#app1-marinedrugs-17-00534){ref-type="app"}).

Using an *in vitro* pro-inflammatory suppression assay, the effects of briaranes **1**--**3** on the release of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein from lipopolysaccharides (LPS)-stimulated RAW264.7 macrophage cells were assessed. The results of pro-inflammatory suppression assay showed that briarane **2** at 10 μM suppressed the release of iNOS to 61.21 ± 9.61% as compared with results of the cells stimulated with LPS only ([Table 3](#marinedrugs-17-00534-t003){ref-type="table"}).

3. Materials and Methods {#sec3-marinedrugs-17-00534}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00534}
------------------------------------

NMR spectra were recorded on a 600 MHz Jeol NMR (model ECZ600R, Tokyo, Japan) or on 500 MHz Varian NMR (model Unity Inova-500, Palo Alto, CA, USA) spectrometers using the residual CHCl~3~ signal (δ~H~ 7.26 ppm) and CDCl~3~ (δ~C~ 77.1 ppm) as internal references for ^1^H and ^13^C NMR, respectively. ESIMS and HRESIMS were obtained from the Bruker mass spectrometer with 7 Tesla magnets (model: SolariX FTMS system, Bremen, Germany). Column chromatography, high-performance liquid chromatography (HPLC), IR spectra, and optical rotation were performed according to our earlier research \[[@B7-marinedrugs-17-00534]\].

3.2. Animal Material {#sec3dot2-marinedrugs-17-00534}
--------------------

Specimens of *J. fragilis* used for this study were collected in June 2017 by self-contained underwater breathing apparatus (SCUBA) divers off the coast of Orchid Island, Taiwan. The samples were stored in a −20 °C freezer until extraction. A voucher specimen was deposited in the NMMBA (voucher no.: NMMBA-TW-GC-2017-08). Identification of the species of this organism was performed by comparison as described in previous studies \[[@B1-marinedrugs-17-00534],[@B2-marinedrugs-17-00534],[@B3-marinedrugs-17-00534]\].

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-17-00534}
-----------------------------

Sliced bodies (wet weight = 423 g) of the coral specimen were prepared and extracted with a 1:1 mixture of methanol (MeOH) and dichloromethane (CH~2~Cl~2~) to give 5.53 g of crude extract, which was partitioned between ethyl acetate (EtOAc) and H~2~O. The EtOAc extract (2.50 g) was then applied to a silica gel column and eluted with gradients of *n*-hexane/acetone (stepwise from 50:1 to 1:2; volume ratio) to furnish 8 fractions (fractions: A−H). Fraction F was purified by normal-phase HPLC (NP-HPLC) using a mixture of *n*-hexane and EtOAc (3.5:1 of volume ratio) as solvent to obtain 14 subfractions (fractions: F1−F14). Fraction F10 was repurified by reverse-phase HPLC (RP-HPLC) using a mixture of MeOH and H~2~O (with volume:volume = 80:20; at a flow rate = 4.0 mL/min) to yield **2** (0.2 mg) and **3** (0.5 mg). Fraction G was separated by NP-HPLC using a mixture of *n*-hexane/EtOAc (1:1; volume ratio) to yield 9 fractions (fractions: G1−G9). Fraction G2 was purified by RP-HPLC using a mixture of MeOH and H~2~O (with volume:volume = 65:35; at a flow rate = 4.0 mL/min) to afford **1** (0.2 mg).

Fragilide R (**1**): Amorphous powder; \[α\]$\underset{D}{\overset{28}{}}$ −288 (*c* 0.07, CHCl~3~); IR (ATR) ν~max~ 3391, 1779, 1736 cm^−1^; ^1^H (600 MHz, CDCl~3~) and ^13^C (150 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-17-00534-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00534-t002){ref-type="table"}; ESIMS: *m/z* 489 \[M + Na\]^+^; HRESIMS: *m/z* 489.20971 (calcd. for C~24~H~34~O~9~ + Na, 489.20950).

Fragilide S (**2**): Amorphous powder; \[α\]$\underset{D}{\overset{28}{}}$ +45 (*c* 0.16, CHCl~3~); IR (ATR) ν~max~ 3447, 1785, 1733 cm^−1^; ^1^H (500 MHz, CDCl~3~) and ^13^C (125 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-17-00534-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00534-t002){ref-type="table"}; ESIMS: *m/z* 547 \[M + Na\]^+^, 549 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 547.17055 (calcd. for C~26~H~33~^35^ClO~9~ + Na, 547.17053).

Fragilide T (**3**): Amorphous powder; \[α\]$\underset{D}{\overset{20}{}}$ −168 (*c* 0.17, CHCl~3~); IR (ATR) ν~max~ 1788, 1737 cm^−1^; ^1^H (600 MHz, CDCl~3~), and ^13^C (150 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-17-00534-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00534-t002){ref-type="table"}; ESIMS: *m/z* 661 \[M + Na\]^+^, 663 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 661.23866 (calcd. for C~32~H~43~^35^ClO~11~ + Na, 661.23861).

3.4. In Vitro Anti-inflammatory Assay {#sec3dot4-marinedrugs-17-00534}
-------------------------------------

The pro-inflammatory suppression assay was employed to assess the activities of the isolated compounds **1**--**3** against the release of iNOS and COX-2 from macrophage cells as the literature reported \[[@B8-marinedrugs-17-00534], [@B9-marinedrugs-17-00534], [@B10-marinedrugs-17-00534], [@B11-marinedrugs-17-00534]\].

4. Conclusions {#sec4-marinedrugs-17-00534}
==============

*J. fragilis* has been demonstrated to have a wide structural diversity of briarane-type diterpenoids that possess various pharmacological properties, particularly in anti-inflammatory activity \[[@B12-marinedrugs-17-00534],[@B13-marinedrugs-17-00534]\]. In our continued study of *J. fragilis*, three previously unreported fragilides R--T (**1**--**3**) were isolated. In the previous studies \[[@B14-marinedrugs-17-00534]\], all the Me-18 attached at C-17 was *cis* to the hydroxy group at C-8, and most of these two groups were α-oriented in briarane derivatives, respectively. Fragilides S and T (**2** and **3**) were proved to be the only two briaranes known to possess hydroxy group at C-8α and methyl group at C-17β, respectively. In the present study, the anti-inflammatory activity of **1**--**3** was assessed using inhibition of pro-inflammatory iNOS and COX-2 release from macrophages. The results indicated that fragilide S (**2**) showed the most potent suppressive effect on iNOS release.

The Supplementary Materials are available online at <https://www.mdpi.com/1660-3397/17/9/534/s1>. Figure S1: ESIMS spectrum of compound 1, Figure S2: HRESIMS spectrum of compound 1, Figure S3: IR spectrum of compound 1, Figure S4: 1H NMR spectrum (600 MHz) of compound 1 in CDCl3, Figure S5: 13C NMR spectrum (150 MHz) of compound 1 in CDCl3, Figure S6: HSQC spectrum of compound 1 in CDCl3, Figure S7: 1H-1H COSY spectrum of compound 1 in CDCl3, Figure S8: HMBC spectrum of compound 1 in CDCl3, Figure S9: NOESY spectrum of compound 1 in CDCl3, Figure S10: ESIMS spectrum of compound 2, Figure S11: HRESIMS spectrum of compound 2, Figure S12: IR spectrum of compound 2, Figure S13: 1H NMR spectrum (600 MHz) of compound 2 in CDCl3, Figure S14: 13C NMR spectrum (150 MHz) of compound 2 in CDCl3, Figure S15: HSQC spectrum of compound 2 in CDCl3, Figure S16: 1H-1H COSY spectrum of compound 2 in CDCl3, Figure S17: HMBC spectrum of compound 2 in CDCl3, Figure S18: NOESY spectrum of compound 2 in CDCl3, Figure S19: ESIMS spectrum of compound 3, Figure S20: HRESIMS spectrum of compound 3, Figure S21: IR spectrum of compound 3, Figure S22: 1H NMR spectrum (600 MHz) of compound 3 in CDCl3, Figure S23: 13C NMR spectrum (150 MHz) of compound 3 in CDCl3, Figure S24: HSQC spectrum of compound 3 in CDCl3, Figure S25: 1H-1H COSY spectrum of compound 2 in CDCl3, Figure S26: MBC spectrum of compound 3 in CDCl3, Figure S27: NOESY spectrum of compound 3 in CDCl3.

###### 

Click here for additional data file.
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marinedrugs-17-00534-t001_Table 1

###### 

^1^H NMR data for briaranes **1**--**3**.

  ------------------------------------------------------------------------------------------------------------------
  Position            1 ^a^                                             2 ^b^                 3 ^a^
  ------------------- ------------------------------------------------- --------------------- ----------------------
  2                   4.83 d (7.2) ^c^                                  5.47 d (9.5)          6.33 d (10.8)

  3α/β                1.91 ddd (15.6, 7.2, 5.4); 2.96 dd (15.6, 12.6)   5.67 dd (16.0, 9.5)   5.78 dd (12.0, 10.8)

  4                   4.18 dd (12.6, 5.4)                               6.72 d (16.0)         5.96 d (12.0)

  6                   5.64 d (10.2, 1.2)                                5.20 s                5.12 br s

  7                   5.97 d (10.2)                                     4.97 br s             4.88 d (4.2)

  9                   4.22 dd (5.4, 3.6)                                5.53 s                5.59 s

  10                  3.20 d (3.6)                                      3.47 s                4.08 s

  12α/β               2.22 m                                            2.24 m; 2.38 m        5.37 dd (5.4, 3.0)

  13α/β               1.96 m; 1.81 m                                    1.84 m; 1.74 m        2.06 m

  14                  4.74 dd (4.2, 1.8)                                4.84 dd (2.5, 2.0)    4.94 dd (4.2, 3.0)

  15                  1.25 s                                            1.18 s                1.16 s

  16a/b               2.09 d (1.2)                                      5.49 s; 5.32 s        5.66 s; 5.48 s

  17                  3.11 q (7.2)                                      2.93 q (7.5)          2.90 q (7.2)

  18                  1.14 d (7.2)                                      1.18 d (7.5)          1.22 d (7.2)

  20a/b               4.97 s; 4.88 s                                    4.93 s; 4.76 s        5.33 s; 4.72 s

  OH-8                \-                                                3.11 s                2.70 s

  OH-9                2.09 d (5.4)                                      \-                    \-

  Acetoxy groups      1.94 s\                                           2.01 s\               2.00 s\
                      1.99 s                                            2.04 s\               2.16 s
                                                                        2.09 s                

  Propionoxy group    \-                                                \-                    1.08 t (7.2)\
                                                                                              2.26 m

  Isovaleroxy group   \-                                                \-                    0.96 d (6.6)\
                                                                                              0.98 d (6.6)\
                                                                                              2.10 m\
                                                                                              2.15 m
  ------------------------------------------------------------------------------------------------------------------

^a^ Spectra measured at 600 MHz in CDCl~3~. ^b^ Spectra measured at 500 MHz in CDCl~3~. ^c^ *J* values (in Hz) in parentheses.

marinedrugs-17-00534-t002_Table 2

###### 

^13^C NMR data for briaranes **1**--**3**.

  --------------------------------------------------------------------
  Position            1 ^a^          2 ^b^              3 ^a^
  ------------------- -------------- ------------------ --------------
  1                   48.2, C ^c^    47.5, C            47.7, C

  2                   73.3, CH       76.9, CH           70.4, CH

  3                   39.7, CH~2~    129.7, CH          130.4, CH

  4                   71.4, CH       135.4, CH          128.7, CH

  5                   146.9, C       142.6, C ^d^       137.5, C

  6                   123.1, CH      66.0, CH ^d^       64.5, CH

  7                   76.4, CH       79.5, CH           76.9, CH

  8                   83.4, C        81.8, C            80.3, C

  9                   74.1, CH       76.3, CH           74.8, CH

  10                  43.0, CH       41.8, CH           37.0, CH

  11                  152.3, C       149.3, C           146.3, C

  12                  29.0, CH~2~    29.1, CH~2~        74.3, CH

  13                  27.8, CH~2~    26.0, CH~2~        31.4, CH~2~

  14                  74.2, CH       74.4, CH           73.0, CH

  15                  15.6, CH~3~    16.4, CH~3~        14.7, CH~3~

  16                  26.2, CH~3~    118.8, CH~2~ ^d^   116.4, CH~2~

  17                  43.8, CH       49.3, CH           50.7, CH

  18                  6.6, CH~3~     9.1, CH~3~         8.7, CH~3~

  19                  176.7, C       174.1, C ^d^       173.9, C

  20                  111.3, CH~2~   111.4, CH~2~       115.2, CH~2~

  Acetoxy groups      21.0, CH~3~\   21.2, CH~3~\       20.7, CH~3~\
                      170.8, C\      170.4, C\          169.7, C\
                      21.3, CH~3~\   21.2, CH~3~\       21.3, CH~3~\
                      170.8, C       170.1, C\          169.6, C
                                     21.2, CH~3~\       
                                     169.2, C           

  Propionoxy group    \-             \-                 8.8, CH~3~\
                                                        27.8, CH~2~\
                                                        172.0, C

  Isovaleroxy group   \-             \-                 22.6, CH~3~\
                                                        22.8, CH~3~\
                                                        25.0, CH\
                                                        43.5, CH~2~\
                                                        172.6, C
  --------------------------------------------------------------------

^a^ Spectra measured at 150 MHz in CDCl~3~. ^b^ Spectra measured at 125 MHz in CDCl~3~. ^c^ Multiplicity deduced by DEPT and HSQC spectra. ^d^ Chemical shfits were assigned by HSQC or HMBC experiments.
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###### 

Effects of briaranes **1**--**3** on LPS-induced pro-inflammatory iNOS and COX-2 protein expression in macrophages.

  Compound           iNOS             COX-2           β-Actin          *n*
  ------------------ ---------------- --------------- ---------------- -----
  Negative Control   1.80 ± 0.21      1.04 ± 0.35     110.02 ± 5.23    2
  LPS                100.01 ± 5.06    100.06 ± 0.43   100.07 ± 8.4     4
  **1**              104.11 ± 16.63   100.51 ± 6.11   105.70 ± 7.05    4
  **2**              61.21 ± 9.61     100.01 ± 5.11   99.29 ± 11.29    3
  **3**              100.91 ± 24.08   96.36 ± 21.31   115.29 ± 3.4     4
  Dexamethasone      5.54 ± 1.72      8.15 ± 5.13     105.21 ± 15.57   4

Data were normalized to those of cells treated with LPS alone, and cells treated with dexamethasone were used as a positive control. Data are expressed as the mean ± SEM (*n* = 2--4).
